http://www.pharmalot.com/2011/09/op-ed-pharma-layoffs-small-minded-survivors/
You must read this and then you will understand why DSI is going the way it is.
Downsizing Trend Leaves Pharma Without the Kinds of Employees It Needs:
By Daniel Hoffman, PhD and president of Pharmaceutical Business Research Associates
In addition to disrupting tens of thousands of lives, the substantial downsizing in pharma over the past two-and-a-half years has changed many companies for the worse. I previously wrote that the guidelines handed down from finance to HR have eliminated many of the more knowledgeable and experienced people at each layoff round because people over age 50 are among the first targets for separation packages. But the dysfunctional legacy is even more pernicious. The resulting culture has created a workforce that is almost entirely at odds with what pharma needs now.
The problem is that the dishonest and unfair approaches the industry has taken to downsizing have left it with many people who are small-minded, politically savvy and safe playing. Gone are the people who acquired the experience to know what doesn’t work after enduring years of self-serving platitudes. Those with sufficient boldness to try something outside the conventional axioms now spend their mornings expanding their Linkedin contacts.
You must read this and then you will understand why DSI is going the way it is.
Downsizing Trend Leaves Pharma Without the Kinds of Employees It Needs:
By Daniel Hoffman, PhD and president of Pharmaceutical Business Research Associates
In addition to disrupting tens of thousands of lives, the substantial downsizing in pharma over the past two-and-a-half years has changed many companies for the worse. I previously wrote that the guidelines handed down from finance to HR have eliminated many of the more knowledgeable and experienced people at each layoff round because people over age 50 are among the first targets for separation packages. But the dysfunctional legacy is even more pernicious. The resulting culture has created a workforce that is almost entirely at odds with what pharma needs now.
The problem is that the dishonest and unfair approaches the industry has taken to downsizing have left it with many people who are small-minded, politically savvy and safe playing. Gone are the people who acquired the experience to know what doesn’t work after enduring years of self-serving platitudes. Those with sufficient boldness to try something outside the conventional axioms now spend their mornings expanding their Linkedin contacts.